Quick Answer
Alaunos Therapeutics, Inc. reported Earnings Per Share Diluted of $2.20 (loss) per share for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +24.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Alaunos Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 66.7%.
- Historical annual values: Fiscal year 2025: $2.20 (loss) per share | Fiscal year 2024: $2.92 (loss) per share | Fiscal year 2023: $21.97 (loss) per share | Fiscal year 2022: $2.61 (loss) per share | Fiscal year 2021: $0.37 (loss) per share | Fiscal year 2020: $0.38 (loss) per share | Fiscal year 2019: $0.70 (loss) per share | Fiscal year 2018: $0.96 per share | Fiscal year 2017: $0.53 (loss) per share | Fiscal year 2016: $1.32 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: